Samsung Biologics Acquires PolyPeptide Group for Obesity Drugs

Samsung Biologics is acquiring Swiss CDMO PolyPeptide Group for $1.46 billion to expand from antibody manufacturing into peptide production, capturing capacity for GLP-1 obesity and diabetes drugs. The deal adds six manufacturing facilities across Europe, the US and India, plus 1,500 skilled staff and existing pharma contracts.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.